Detalhe da pesquisa
1.
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients.
J Autoimmun
; 147: 103244, 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38797050
2.
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
J Eur Acad Dermatol Venereol
; 37(1): 93-103, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36156312
3.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Eur Acad Dermatol Venereol
; 37(5): 1017-1027, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695061
4.
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report.
Dermatol Ther
; 35(12): e15952, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36269298
5.
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.
J Pers Med
; 14(2)2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38392619
6.
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.
Dermatol Reports
; 16(1): 9722, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38623366
7.
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review.
Clin Cosmet Investig Dermatol
; 17: 593-604, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38495913
8.
Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series.
Int J STD AIDS
; 35(1): 67-70, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691387
9.
Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.
J Dermatol
; 51(6): 839-843, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38292002
10.
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
Dermatol Ther (Heidelb)
; 14(4): 919-932, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38509380
11.
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Dermatol Ther (Heidelb)
; 14(6): 1649-1657, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748344
12.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Clin Med
; 13(2)2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38256629
13.
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Dermatol Pract Concept
; 14(2)2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416060
14.
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
J Dermatolog Treat
; 35(1): 2350760, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714323
15.
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.
Melanoma Res
; 33(2): 152-154, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36728879
16.
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series.
J Dermatolog Treat
; 34(1): 2183729, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809172
17.
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study.
Dermatol Ther (Heidelb)
; 13(2): 651-660, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617589
18.
Long-term management of pediatric psoriasis with ixekizumab: a case report.
J Dermatolog Treat
; 34(1): 2198622, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37000510
19.
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
J Dermatolog Treat
; 34(1): 2220849, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37288760
20.
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study.
Dermatol Reports
; 15(3): 9692, 2023 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37790655